KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gilead Sciences (GILD) Operating Expenses (2016 - 2025)

Gilead Sciences (GILD) has disclosed Operating Expenses for 17 consecutive years, with $5.9 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 16.1% year-over-year to $5.9 billion, compared with a TTM value of $19.4 billion through Dec 2025, down 28.31%, and an annual FY2025 reading of $19.4 billion, down 28.31% over the prior year.
  • Operating Expenses was $5.9 billion for Q4 2025 at Gilead Sciences, up from $4.4 billion in the prior quarter.
  • Across five years, Operating Expenses topped out at $11.0 billion in Q1 2024 and bottomed at $3.5 billion in Q1 2021.
  • Average Operating Expenses over 5 years is $5.2 billion, with a median of $4.6 billion recorded in 2023.
  • The sharpest move saw Operating Expenses skyrocketed 136.88% in 2024, then plummeted 59.76% in 2025.
  • Year by year, Operating Expenses stood at $6.3 billion in 2021, then decreased by 18.75% to $5.1 billion in 2022, then increased by 7.42% to $5.5 billion in 2023, then dropped by 7.0% to $5.1 billion in 2024, then grew by 16.1% to $5.9 billion in 2025.
  • Business Quant data shows Operating Expenses for GILD at $5.9 billion in Q4 2025, $4.4 billion in Q3 2025, and $4.6 billion in Q2 2025.